DelveInsight’s, “Colorectal Cancer Pipeline Insight 2023” report provides comprehensive insights about 195+ Colorectal Cancer companies and 200+ pipeline drugs in the Colorectal Cancer pipeline landscape. It covers the Colorectal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Colorectal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Colorectal Cancer Pipeline Report
- DelveInsight’s Colorectal Cancer pipeline report depicts a robust space with 195+ companies working to develop 200+ pipeline Colorectal Cancer.
- The leading Colorectal Cancer Companies working in the market include Exelixis, Mirati Therapeutics, Merck Sharp & Dohme LLC, Daiichi Sankyo Company, Inspirna, LyellI mmunopharma, Genentech, Cantargia AB, Arcus Biosciences Inc., Neogap Therapeutics AB, Criterium Inc., Daiichi Sankyo Inc., Bristol-Myers Squibb, Celyad Oncology SA, Pfizer, Akeso, Menarini Group, Elpiscience (Suzhou) Biopharma Ltd., Beyond Bio Inc., Shanghai Henlius Biotech, Rotta pharm Biotech, Innovative Cellular Therapeutics Inc., BioNTech SE, and others.
- Promising Colorectal Cancer Pipeline Therapies in the various stages of development includes CPT-11 and TS-1, ZN-c3, Encorafenib, Cetuximab, Bevacizumab, Oxaliplatin, Capecitabine, Regorafenib (Stivarga, BAY73-4506), Leucovorin, and others.
- January 2024: Daiichi Sankyo Inc. announced a study of Phase 2 clinical trials for DS-8201a 5.4 mg/kg Q3W. This study will evaluate the efficacy, safety, and pharmacokinetics of Trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor 2 (HER2)-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC).
- December 2023: Bristol-Myers Squibb announced a study of Phase 3 clinical trials for Ipilimumab, Oxaliplatin, Leucovorin, Fluorouracil, and Irinotecan. The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), Objective Response Rate (ORR), and Overall Survival (OS), achieved by nivolumab in combination with ipilimumab or by nivolumab monotherapy in participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer (mCRC). This study will also compare nivolumab plus ipilimumab combination vs chemotherapy for treatment of MSI-H/dMMR mCRC participants.
- December 2023: Genentech Inc. announced a study of Phase 1 clinical trials for BLYG8824A. This study will evaluate the safety, tolerability, and pharmacokinetics of BLYG8824A and will make a preliminary assessment of the anti-tumor activity of BLYG8824A in patients with locally advanced or metastatic colorectal cancer.
- December 2023: Agenus Inc. announced a study of Phase 2 clinical trials for Botensilimab and Balstilimab. This is an open-label, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab or standard-of-care treatments in participants with refractory metastatic colorectal cancer.
- December 2023: Novartis Pharmaceuticals announced a study of Phase 1 clinical trials for Dabrafenib, LTT462, Trametinib, LXH254, and TNO155. A phase Ib, open-label platform study of select drug combinations chosen in order to characterize safety and tolerability of each treatment arm tested and to identify recommended doses and regimens for future studies.
Request a sample and discover the recent advances in Colorectal Cancer Drugs @ Colorectal Cancer Pipeline Outlook Report
In the Colorectal Cancer Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Colorectal Cancer clinical trials studies, NDA approvals (if any), and product development activities comprising the technology, Colorectal Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details. The assessment part of the report embraces, in depth Colorectal Cancer commercial assessment and clinical assessment of the Colorectal Cancer pipeline products under development.
Colorectal Cancer Overview
CRC is a multifactorial disease. The epithelial cells of colorectal mucosa can undergo hyperplasia, atypical hyperplasia (mild, moderate, or severe), and adenomas that can eventually develop into carcinoma. This process is usually initiated by carcinogenic factors, causing structural changes in DNA and leading to the malignant transformation of cells into cancer. Morphology includes epithelial hyperplasia, atypical hyperplasia, adenoma formation, carcinoma in situ, and invasive carcinoma.
Colorectal Cancer Emerging Drugs
- XL092 : Exelixis
- Adagrasb: Mirati Therapeutics
- Olaparib : Merck Sharp & Dohme LLC/Astrazeneca
- DS-8201: Daiichi Sankyo
- Ompenaclid: Inspirna
- LYL845: Lyell Immunopharma
- RG6286: Genentech
Colorectal Cancer Therapeutics Assessment
There are approx. 195+ Colorectal Cancer companies which are developing the therapies for Colorectal Cancer. The Colorectal Cancer companies which have their Colorectal Cancer drug candidates in the most advanced stage, i.e. phase III include, Exelixis. The Colorectal Cancer pipeline report proffers an integral view of the emerging Colorectal Cancer segmented by stage, product type, molecule type, and route of administration.
Find out more about Colorectal Cancer Analysis @ Colorectal Cancer Drugs
DelveInsight’s Colorectal Cancer pipeline report covers around 200+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Colorectal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Colorectal Cancer Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Dive deep into rich insights for new Colorectal Cancer, visit @ Colorectal Cancer Treatment Landscape
Scope of the Colorectal Cancer Pipeline Report
- Coverage- Global
- Colorectal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Colorectal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Colorectal Cancer Companies- Exelixis, Mirati Therapeutics, Merck Sharp & Dohme LLC, Daiichi Sankyo Company, Inspirna, LyellI mmunopharma, Genentech, Cantargia AB, Arcus Biosciences Inc., Neogap Therapeutics AB, Criterium Inc., Daiichi Sankyo Inc., Bristol-Myers Squibb, Celyad Oncology SA, Pfizer, Akeso, Menarini Group, Elpiscience (Suzhou) Biopharma Ltd., Beyond Bio Inc., Shanghai Henlius Biotech, Rotta pharm Biotech, Innovative Cellular Therapeutics Inc., BioNTech SE, and others.
- Colorectal Cancer Pipeline Therapies- CPT-11 and TS-1, ZN-c3, Encorafenib, Cetuximab, Bevacizumab, Oxaliplatin, Capecitabine, Regorafenib (Stivarga, BAY73-4506), Leucovorin, and others.
For further information on the Colorectal Cancer Pipeline Therapeutics, reach out @ Colorectal Cancer Therapeutics Segmentation
Table of Content
- Introduction
- Colorectal Cancer Executive Summary
- Colorectal Cancer: Overview
- Colorectal Cancer Pipeline Therapeutics
- Colorectal Cancer Therapeutic Assessment
- Late Stage Products (Phase III)
- Comparative Analysis
- XL092: Exelixis
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Early Stage Products (Phase I)
- LYL845: Lyell Immunopharma
- Inactive Products
- Colorectal Cancer Key Companies
- Colorectal Cancer Products
- Colorectal Cancer Unmet Needs
- Colorectal Cancer Market Drivers and Barriers
- Colorectal Cancer Future Perspectives and Conclusion
- Colorectal Cancer Analyst Views
- Colorectal Cancer Key Companies
- Appendix
Find out more about Colorectal Cancer Therapeutics Assessment @ Colorectal Cancer Preclinical and Discovery Stage Products
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/mouth-neoplasms-market